VPC51299 is a potent low micromolar inhibitor containing a vinyl phosphonate head group and possessing a half-life of approximately 90 min in rats when dosed intravenously. Previously developed LPA1/LPA3 receptor antagonists contain a labile phosphate head group which impairs evaluation of scaffold LPA receptor antagonists in vivo. VPC51299 has replaced the phosphate with a more stable head group while retaining potency at both LPA1 and LPA3 to facilitate future in vivo studies of the biological functions of these receptors.Refer: J.E. East, et al. (2011). Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. Medchemcomm 2:325-330.
This product is covered by Patent Number US 8,283,339 B2. Avanti manufactures this under license from University of Virginia.
Avanti Polar Lipids公司是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供 1000 种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,Avanti Polar Lipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。
Avanti Polar Lipids, Inc., has a long history of 50 years creating the highest purity lipids available. Our passion for high quality and unique products is only exceeded by our excellent reputation in the marketplace. Although we are known for our lipids, we are More than Lipids. We offer solutions for the entire product cycle…Research to Commercialization.
Avanti Polar Lipids公司的主要产品和服务包括:
(1)Research Products
Highest Purity Lipid Reagents
(2)cGMP Manufacturing
API & Contract Manufacturing
(3)Adjuvants
Immunotherapy & Vaccine Development
(4)Analytical Services
Lipid Analysis
(5)Lipidomics
Mass Spec Standards, Antibodies & Lipid Toolbox
(6)Formulations
Liposomes & Nanoparticles
(7)Equipment
Liposome Production Tools
(8)Custom Services
Synthesis & Beyond